Pharmacoeconomical rationale for switching of patients with type 1 diabetes mellitus to the short-acting insulin analogue Aspart (Novorapid*)

Abstract

The consequences of switching of patients with type 1 diabetes mellitus (DM-1) to the short-acting insulin analogue Aspart (Novorapid*) were pharmacoeconomically analyzed. The study has indicated that switching of patients with DM-1 to the short-acting insulin analogue Aspart leads in actual practice to the decreased levels of Hb A_k due to its pharmacological properties ensuring the maximum simulation of physiological pancreatic insulin secretion, which is followed by a reduction in the absolute risk of new cases and by progression of existing chronic vascular complications as compared with the use of short-acting insulin analogue Actrapid. Calculation of the cost of treatment of all prevented vascular complications due to DM has shown that the short-acting insulin analogue Novorapid is more cost-effective agent than Actrapid.